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Interferon- (IFN) treatment of adipocytes results in
a down-regulation of the peroxisome proliferator-acti-
vated receptor  (PPAR). The decrease in PPAR ex-
pression is mediated by inhibition of PPAR synthesis
and increased degradation of PPAR. In this study, we
demonstrate that both PPAR1 and PPAR2 are tar-
geted to the proteasome under basal conditions and that
PPAR1 is more labile than PPAR2. The IFN-induced
increase in PPAR turnover is blocked by proteasome
inhibition and is accompanied by an increase in PPAR-
polyubiquitin conjugates. In addition, IFN treatment
results in the transcriptional activation of PPAR. Sim-
ilar to ligand-dependent activation of PPAR, IFN-in-
duced activation was greater in the phosphorylation-
deficient S112A form of PPAR when compared with
wild-type PPAR. Moreover, the inhibition of ERKs 1
and 2 with a MEK inhibitor, U1026, lead to an inhibition
in the decay of PPAR proteins, indicating that serine
phosphorylation influences the degradation of PPAR
in fat cells. Our results also demonstrate that the pro-
teasome-dependent degradation of PPAR does not re-
quire nuclear export. Taken together, these results in-
dicate that PPAR is targeted to the ubiquitin-
proteasome pathway for degradation under basal
conditions and that IFN leads to an increased targeting
of PPAR to the ubiquitin-proteasome system in a proc-
ess that is affected by ERK-regulated serine phosphoryl-
ation of PPAR proteins.
PPAR1 is a member of the nuclear hormone receptor family,
a group of transcription factors that are activated by small
lipophilic ligands (1). PPAR exists as two isoforms, PPAR1
and PPAR2, which are produced by a combination of different
promoters and alternative splicing (2). There is also a PPAR3
gene that codes for a protein that is identical to PPAR1 (3).
PPAR1 is predominantly expressed in fat cells but occurs in
low levels in multiple tissues. PPAR2 has an N-terminal ex-
tension of 30 amino acids and is very highly expressed in
adipocytes (4, 5). Deletion of the PPAR gene in mice results in
placental dysfunction and embryonic lethality (6, 7).
PPAR has been implicated in the regulation of systemic
insulin sensitivity. This was first demonstrated when PPAR
was shown to be a functional receptor for the synthetic anti-
diabetic thiazolidinediones (TZDs) (8). Thiazolidinediones are
specific high affinity ligands for PPAR and the order of their
receptor binding affinities in vitro mirrors their antihypergly-
cemic activity in vivo (9). Direct evidence for the association
between PPAR and insulin sensitivity comes from genetic
studies showing that mutations in the ligand-binding domain
of PPAR are associated with severe insulin resistance. Al-
though not obese, these patients developed type 2 diabetes as
well as early onset hypertension (10). Also, insulin has been
shown to acutely regulate the expression of PPAR in human
adipocytes (11), and mice that only express one copy of the
PPAR gene have been shown to be more sensitive to insulin
(12). We have recently demonstrated that IFN results in a
substantial loss of PPAR expression by regulating two cellular
events: 1) targeting PPAR to the proteasome for degradation,
and 2) inhibiting the synthesis of PPAR (13). Moreover, pro-
longed IFN treatment of 3T3-L1 adipocytes also results in
the development of insulin resistance (13) and supports the
hypothesis that PPAR is involved in conferring insulin
sensitivity.
Interferon- (IFN) is a cytokine that is primarily known for
its roles in immunological responses but has also been shown to
affect fat metabolism and adipocyte gene expression. In adipo-
cytes, IFN treatment results in a decrease of lipoprotein lipase
(LPL) activity and increased lipolysis (14). In 3T3-F442 adipo-
cytes, exposure to IFN results in a decreased expression of
lipoprotein lipase and fatty acid synthase. Also, in various
rodent preadipocyte cell lines, IFN inhibits the differentiation
of preadipocytes (15–17). Acute IFN treatment of cultured and
native rat adipocytes results in a dose- and time-dependent
activation of STATs 1 and 3 (18). Moreover, there are studies
(19–21) linking IFN and insulin resistance in humans. IFN
has been implicated in the development of insulin resistance
during viral infections (20), and IFN therapy of cancer pa-
tients has been associated with the development of hypergly-
cemia (21).
The ubiquitin-proteasome pathway is essential for the deg-
radation of short lived proteins, the levels of which are regu-
lated constitutively or in response to changes in the cellular
environment (22, 23). Transcription factors and tumor suppres-
sors are among the proteins regulated by the ubiquitin-protea-
some pathway, and included in this group are members of the
nuclear hormone receptor superfamily (24, 25). Ligand-depend-
ent down-regulation by the ubiquitin-proteasome system has
been demonstrated for several members of the nuclear hor-
mone receptor family, including the estrogen (26, 27), proges-
terone (28), thyroid hormone (29), and aryl hydrocarbon recep-
tors (30).
Substrates of the ubiquitin-proteasome system are targeted
to the proteasome after covalent attachment of multiple ubiq-
uitin molecules. Ubiquitin, a 76 amino acid protein, is initially
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activated by E1, the ubiquitin-activating enzyme. Activated
ubiquitin is then transferred to a ubiquitin-conjugating enzyme
(E2), which generally shuttles ubiquitin to ubiquitin ligase
(E3). E3 is bound to the targeted substrate and catalyzes the
covalent attachment of ubiquitin to the substrate. Once the
first ubiquitin is transferred to the substrate, a polyubiquiti-
nation chain is generated via a series of isopeptide linkages.
The multiubiquitinated substrate protein is then degraded by
the 26 S proteasome in an ATP-dependent manner (31).
Our recent studies (13) have shown that acute IFN treat-
ment of 3T3-L1 adipocytes results in a repression of PPAR
transcription that is independent of new protein synthesis. Yet,
we also demonstrated that the half-life of PPAR proteins was
shorter following IFN treatment. In the current investigation,
we observed that proteasomal inhibitors attenuate the TZD-
and IFN-induced decrease in PPAR expression. Moreover,
we demonstrate that IFN treatment is associated with an
increase in the formation of polyubiquitin-PPAR conjugates in
3T3-L1 adipocytes. Together, these data indicate that IFN
signaling results in the increased targeting of PPAR to the
ubiquitin-proteasome system in adipocytes. In addition, we
have shown that like TZDs, IFN increases the transcriptional
activity of PPAR. Also, the IFN-induced activation of a phos-
phorylation-deficient mutant of PPAR2 (S112A) is substan-
tially greater than the IFN activation of wild-type PPAR2.
Our results suggest that phosphorylation of PPAR2 at Ser112
contributes to the targeting of PPAR to the ubiquitin-protea-
some pathway. Finally, these studies indicate that the IFN-
mediated ubiquitin-proteasome-dependent degradation of
PPAR occurs in the nucleus.
EXPERIMENTAL PROCEDURES
Materials—Dulbecco’s modified Eagle’s medium (DMEM), Opti-
MEM, and fetal bovine serum were purchased from Invitrogen. Calf
serum was purchased from Sigma. Murine IFN was purchased from
Roche Molecular Biochemicals. PPAR monoclonal (E-8, no. sc-7273)
and polyclonal (H-100, no. sc-7196) antibodies, Mdm2 monoclonal
(SMP14, no. sc-965) antibody, and a STAT 5A polyclonal (L-20, no.
sc-1081) antibody were purchased from Santa Cruz Biotechnology.
Monoclonal anti-ubiquitin (no. 13–1600) was purchased from Zymed
Laboratories Inc. The proteasome inhibitors epoxomicin, lactacystin,
and MG132 (N-carbobenzoxyl-Leu-Leu-Leucinal) were purchased from
Boston Biochemicals. A luciferase assay system, pSV--galactosidase
control vector, and a -galactosidase enzyme assay kit were purchased
from Promega. FuGENE 6 was purchased from Roche Molecular Bio-
chemicals. Darglitazone was kindly provided by Pfizer.
Constructs—The pSVSport plasmids encoding wild-type PPAR and
the S112A PPAR mutant as well as DR-1 luciferase were the generous
gift of Dr. Bruce Spiegelman (Dana Farber Cancer Institute). The
HA-ubiquitin plasmid and leptomycin B (LMB) were kindly provided
by Dr. Dirk Bohmann (European Molecular Biology Laboratories) and
Dr. Minoru Yoshida (The University of Tokyo), respectively.
Cell Culture—Murine 3T3-L1 preadipocytes were plated and grown
to 2-days postconfluence in DMEM with 10% calf serum. The medium
was changed every 48 h. Cells were induced to differentiate by changing
the medium to DMEM containing 10% fetal bovine serum and 0.5 mM
3-isobutyl-methylxanthine, 1 M dexamethasone, and 1.7 M insulin
(MDI). After 48 h, this medium was replaced with DMEM supple-
mented with 10% fetal bovine serum, and the cells were maintained in
this medium until used for experimentation. NIH 3T3 cells were grown
in DMEM with 10% calf serum.
Preparation of Whole Cell Extracts—Cell monolayers were rinsed
with phosphate-buffered saline (PBS) and harvested in a lysis buffer
containing 10 mM Tris-Cl, pH 7.4, 150 mM NaCl, 1 mM EGTA, 1 mM
EDTA, 1% Triton X-100, 0.5% Nonidet P-40, 1 M phenylmethylsulfonyl
fluoride, 1 M pepstatin, 50 trypsin inhibitory milliunits of aprotinin, 10
M leupeptin, and 2 mM sodium vanadate. Samples were extracted on
ice for 30 min prior to centrifugation at 10,000  g for 15 min. The
resulting supernatants were analyzed for protein content by BCA anal-
ysis (Pierce) according to the manufacturer’s instructions and stored at
80 °C.
Preparation of Nuclear/Cytosolic Extracts—Cell monolayers were
rinsed with PBS and harvested in a nuclear homogenization buffer
(NHB) containing 20 mM Tris-Cl, pH 7.4, 10 mM NaCl and 3 mM MgCl2.
Nonidet P-40 was added to a final concentration of 0.15%, and the cells
were homogenized with 16 strokes in a Dounce homogenizer. The re-
sulting homogenate was centrifuged at 1500 rpm for 5 min, and the
supernatant was saved as cytosolic extract. The nuclear pellet was
twice resuspended in 0.5 volume of a nuclear homogenization buffer
and centrifuged as before. The nuclear pellet was then resuspended in
an extraction buffer containing 20 mM HEPES pH 7.9, 420 mM NaCl,
0.2 mM EDTA and 25% glycerol. Nuclei were extracted for 30 min on ice
followed by incubation with 200 units of DNase I at room temperature
for 15 min. Finally, the sample was centrifuged at 15,000 rpm for 10
min at 4 °C. The resulting nuclear extract and the previously obtained
cytosolic extract were analyzed for protein content by BCA analysis
(Pierce) according to the manufacturer’s instructions and stored at
80 °C.
Gel Electrophoresis and Immunoblotting—Proteins were separated
in 12% polyacrylamide (National Diagnostics) gels containing SDS ac-
cording to Laemmli (32) and transferred to nitrocellulose (Bio-Rad) in
25 mM Tris, 192 mM glycine, and 20% methanol. Following transfer, the
membrane was blocked in 4% milk overnight at 4 °C. The immunoblots
were visualized with horseradish peroxidase-conjugated secondary an-
tibodies (Sigma) and enhanced chemiluminescence (Pierce).
Transient Transfection and Luciferase Assay—NIH 3T3 cells were
grown to 60–70% confluence and transiently transfected with either
wild-type PPAR2 or PPAR2 S112A. To measure PPAR activity, the
cells were cotransfected with DR-1 luciferase and pSV--galactosidase
to normalize for transfection efficiency. FuGENE 6 was used according
to the manufacturer’s instructions and a FuGENE 6 to DNA ratio of 3:2
was used in the transfections. Transient transfections were carried out
in OptiMEM for 8 h. After 8 h, the media were replaced with DMEM
supplemented with 10% calf serum, and the cells were incubated over-
night. Twenty-four hours after transfection, the cells were treated with
IFN (100 units/ml) or darglitazone (TZD) (2.5 M), and the cells were
harvested 6 h later. Cell lysates were prepared and analyzed for lucif-
erase activity and -galactosidase activity according to the manufac-
turer’s instructions (Promega). PPAR transcriptional activity was re-
ported as the ratio of luciferase activity (relative light units) to
-galactosidase activity.
Ubiquitin Conjugation Assay—NIH 3T3 cells were transfected with 2
g of PPAR alone or in combination with 4 g of HA-ubiquitin per 100
mm plate using FuGENE 6 as described above. After 24 h, the cells
were treated with 10 M MG132 for 2 h prior to the addition of IFN
(100 units/ml). The cells were harvested after 15- and 30-min incuba-
tions and lysed on ice in PBS, pH 7.0, containing 1% Triton X-100, 10
mM N-ethylmaleimide, 1 mM phenylmethylsulfonyl fluoride, 1 M pep-
statin and 10 M leupeptin. Immunoprecipitations were performed by
incubation with a polyclonal anti-PPAR followed by incubation with
protein A-Sepharose (RepliGen). PPAR-ubiquitin complexes were de-
tected by Western blotting with an anti-HA antibody.
3T3-L1 adipocytes were serum-deprived overnight in OptiMEM, fol-
lowed by incubation with 10 M MG132 for 2 h. At the end of 2 h, IFN
(100 units/ml) was added, and the cells were harvested after 15- and
30-min incubations and lysed on ice in PBS containing 1% Triton X-100,
10 mM N-ethylmaleimide, 1 mM EDTA, 1 mM phenylmethylsulfonyl
fluoride, 1 M pepstatin, and 10 M leupeptin. Immunoprecipitations
were performed with a polyclonal anti-PPAR, and PPAR-ubiquitin
complexes were detected by Western blotting using both anti-PPAR
(monoclonal) and anti-ubiquitin antibodies.
PPAR Stability in Vivo—Experiments using 3T3-L1 adipocytes
were carried out in the presence or absence of cycloheximide (5 M) to
examine the effect of IFN on the half-life of PPAR proteins. The
half-lives of PPAR1 and PPAR2 were calculated based on first order
decay after quantitation of Western blot data using Un-Scan-It software
(Silk Scientific, Inc). IFN was added at 100 units/ml and darglitazone
was added at 2.5 M, where indicated. The adipocytes were incubated
with one of three proteasome inhibitors (5 M lactacystin, 100 nM
epoxomicin, or 10 M MG132) in experiments designed to assay protea-
some targeting of PPAR. In these experiments, the cells were prein-
cubated with the proteasome inhibitor for 15–30 min prior to adding the
ligand or cycloheximide. A MAPK/ERK kinase (MEK) inhibitor, U0126
(5 M), was used to assay involvement of ERK1/2 in the turnover of
PPAR, and the cells were preincubated with U0126 for 30–45 min.
Leptomycin B (10 nM) was added as an inhibitor of CRM-1-dependent
nuclear export (33). Cells were pretreated with leptomycin B for 0.5–1
h prior to the addition of ligand or cycloheximide. Vehicle control
additions were performed with either Me2SO (for proteasome inhibi-
tors, TZDs, and U0126) or ethanol (for leptomycin B).
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RESULTS
Basal and IFN-mediated Targeting of PPAR to the Protea-
some—We have previously shown that treatment of 3T3-L1
adipocytes with IFN leads to a decrease in the half-life of both
PPAR proteins (13). Recent studies by Spiegelman and co-
workers (34) have shown that TZDs target PPAR for protea-
some-mediated degradation. These results suggest that target-
ing to the proteasome is an important regulatory event in the
control of PPAR expression. Therefore, we examined PPAR
expression in the presence of three distinct proteasome inhib-
itors. As shown in Fig. 1, treatment of 3T3-L1 adipocytes with
either epoxomicin, lactacystin, or MG132 resulted in an in-
crease in the levels of PPAR proteins under basal conditions
or in the presence of IFN or TZD. Lactacystin and epoxomicin
are highly specific proteasome inhibitors and confirm that the
observed effects on degradation are due to proteasomal target-
ing (35, 36). As shown in Fig. 1, under steady-state conditions,
IFN treatment of 3T3-L1 adipocytes leads to a substantial loss
of PPAR when compared with control levels. The decrease in
PPAR after IFN treatment is slightly greater than the de-
crease associated with the presence of synthetic ligand (TZD).
Inhibition of the proteasome substantially reduces the IFN-
induced decrease in PPAR expression. These results indicate
that the loss of PPAR following IFN treatment is mediated
by the targeting of PPAR to the 26 S proteasome. Interest-
ingly, PPAR levels in both IFN- and TZD-treated adipocytes
in the presence of proteasome inhibitors are less than the
control levels under the same conditions. This result is consist-
ent with studies that demonstrate that both IFN and TZDs
can also down-regulate PPAR at the mRNA level (13, 37).
IFN-mediated Ubiquitin-PPAR Conjugation—Ubiquitin-
proteasome-dependent degradation of a substrate requires two
separate steps. First, the substrate is targeted to the protea-
some via covalent tagging of the substrate with a polyubiquitin
chain. The polyubiquitin-conjugated substrate is then recog-
nized by the 26 S proteasome (22). These polyubiquitin-sub-
strate conjugates are short lived, high molecular mass inter-
mediates of the ubiquitin-proteasome pathway. Because IFN
affects PPAR decay and this effect can be modulated by pro-
teasome inhibitors, we hypothesized that there would be an
increase in polyubiquitin-PPAR conjugates after IFN treat-
ment. To test this theory, we examined the formation of endog-
enous PPAR-ubiquitin adducts in 3T3-L1 adipocytes. PPAR
proteins were immunoprecipitated from whole cell extracts
that had been incubated in the presence or absence of IFN for
the times indicated in Fig. 2. The immunoprecipitations were
analyzed by immunoblotting using either an anti-PPAR anti-
body (Fig. 2A) or an anti-ubiquitin (Fig. 2B) antibody. As shown
in Fig. 2, PPAR was detected in high molecular mass forms
that are present under basal conditions and with increased
intensity after IFN treatment. We also ectopically expressed
octameric HA-tagged ubiquitin and PPAR2 in NIH 3T3 cells
and observed ubiquitin conjugation of PPAR under basal con-
ditions and a significant increase in PPAR ubiquitin conjuga-
tion following IFN treatment (data not shown).
IFN-mediated Activation of PPAR—Based on our previous
studies showing that IFN treatment of cultured adipocytes
has the dual effect of suppressing PPAR transcription and
increasing PPAR turnover (13), we hypothesized that IFN
treatment may also decrease the transcriptional activity of
PPAR. To test this prediction, we assayed the transcriptional
activity of PPAR in NIH 3T3 cells using a luciferase reporter
(DR1 luciferase) construct containing three PPAR response
elements. This construct has previously been used to measure
PPAR activity (34, 38). In this experiment, we also examined
the effect of IFN on the transcriptional activity of the phos-
phorylation-deficient PPAR2 S112A mutant. Numerous stud-
ies have shown that this mutant is more transcriptionally
active and that phosphorylation at this site is associated with
reduced PPAR activity (39–41). To measure PPAR activity,
NIH 3T3 cells were transiently cotransfected with DR1 lucif-
erase and PPAR2 or PPAR2 S112A in pSVSport vectors in
the presence and absence of IFN or TZD. As shown in Fig. 3,
IFN treatment activates PPAR2 to the same extent as the
ligand-dependent activation associated with TZD treatment. In
FIG. 1. PPAR is targeted to the proteasome under basal conditions and after IFN or TZD treatment. Whole cell extracts were
prepared from fully differentiated 3T3-L1 adipocytes that were untreated or treated with 100 units/ml IFN or 2.5 M TZD. Proteasome activity
was inhibited with epoxomicin (100 nM), lactacystin (5 M), or MG132 (10 M). Steady-state levels of PPAR were measured after 6 h. One hundred
micrograms of each extract was separated by SDS-PAGE, transferred to nitrocellulose, and subjected to Western blot analysis. The molecular mass
of each protein is indicated to the left of the blot in kDa. The detection system was horseradish peroxidase-conjugated secondary antibodies (Sigma)
and ECL (Pierce). This was a representative experiment independently performed three times.
FIG. 2. IFN treatment is associated with an increase in
PPAR-ubiquitin conjugates in 3T3-L1 adipocytes. Fully differ-
entiated 3T3-L1 adipocytes were treated with IFN (100 units/ml) for
15 and 30 min after preincubation with MG132 (20 M) for 2 h. Control
samples were incubated for the same time period without the addition
of IFN. Whole cell extracts were harvested and immunoprecipitations
were performed as described under “Experimental Procedures” using
anti-PPAR. Western analysis was performed using either anti-PPAR
(left) or anti-ubiquitin (right). HC represents IgG heavy chain.
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addition, activity of the PPAR2 S112A was greater than wild-
type PPAR2, and the transcriptional activity of the mutant
was also significantly induced by IFN treatment. However,
the mutant was more potently activated by TZD treatment.
The Role of Ser112 Phosphorylation in the Decay of PPAR—
Because IFN and TZDs both activate PPAR and target it for
degradation, we hypothesized that regulators of PPAR acti-
vation could also contribute to PPAR degradation. Therefore,
we examined the contribution of PPAR Ser112 phosphoryla-
tion on PPAR degradation because phosphorylation at this
site has profound effects on PPAR activation. Fully differen-
tiated 3T3-L1 adipocytes were pretreated with the MEK inhib-
itor, U0126, prior to the addition of IFN or a vehicle control.
Turnover of PPAR was then measured in the presence or
absence of cycloheximide. As shown in Fig. 4A, the turnover of
both PPAR1 and 2 was prolonged in the presence of the MEK
inhibitor (control  MEK I). We also observed that inhibition of
ERK1/2 activity abrogates the IFN-mediated decrease in the
half-life of PPAR (Fig. 4A, IFN  MEK I). The results in Fig.
4A clearly demonstrate that the presence of the MEK inhibitor
suppresses the decay of PPAR proteins in adipocytes under
control and IFN-treated conditions. We also examined the
effect of IFN and/or MEK I on PPAR levels in the absence of
cycloheximide. The results in Fig. 4B confirm that ERKs 1 and
2 and play a role in degradation of PPAR proteins under basal
as well as IFN-mediated conditions. In Fig. 4, A and B, the
expression of STAT 5A is shown as a loading control. The
results in Fig. 4A also indicate that the decay of PPAR is much
quicker than the decay of PPAR2. Therefore, we performed an
additional decay experiment to compare the decay of 1 and 2.
Fully differentiated 3T3-L1 adipocytes were treated with cyclo-
heximide, and whole cell extracts were isolated at various
times over a 6 h period. Fig. 5A shows the decay of PPAR
proteins under basal conditions. The 1 and 2 half-lives were
calculated to be 58 min and 1.45 h, respectively. The bottom
panel of Fig. 5A represents an enlarged display of four of the
time points from the top panel. As shown in this panel, we were
also able to resolve the two bands of PPAR1, which represent
the Ser112-phosphorylated (upper band) and unphosphorylated
forms of the protein. The decay experiment in Fig. 5A clearly
demonstrates that PPAR1 is more labile than 2. In addition,
the unphosphorylated 1 disappears quicker than the phospho-
rylated form of 1. This pattern was also observed in the
presence of IFN. (Fig. 5B).
Cellular Location of PPAR Degradation—The majority of
PPAR proteins are found in the nucleus, and this raises the
possibility that the nuclear, rather than cytosolic, ubiquitin-
proteasome components may mediate the degradation of
PPAR. To address this question, we treated 3T3-L1 adipocytes
with IFN alone or in the presence of either MG132 or lepto-
mycin B (Fig. 6). LMB acts as an irreversible inhibitor of the
CRM-1-dependent nuclear export pathway via the modification
of Cys529 of CRM-1 (33) and has been used to determine
whether nuclear export is required for the degradation of nu-
clear proteins (42–44). We examined the decay of PPAR pro-
teins following IFN treatment in the presence of either
MG132 or LMB. The results in Fig. 6 indicate that MG132
prolongs the half-life of PPAR proteins, and the presence of
LMB has no effect on PPAR decay. To confirm LMB activity,
we assayed the cellular location of Mdm2 in 3T3-L1 adipocytes
FIG. 3. IFN mediates transcriptional activation of both wild-
type PPAR and PPAR S112A. NIH 3T3 cells were cotransfected
with pDR1-luciferase and either wild-type PPAR or PPAR S112A.
The cells were also transfected with pSV--galactosidase to correct for
variability in transfection efficiency. After 24 h, the cells were incu-
bated with IFN (100 units/ml) or darglitazone (TZD, 2.5 M) and
harvested 6 h later. PPAR transcriptional activity was determined by
calculating the ratio of luciferase activity (relative light units, RLU) to
-galactosidase activity. The experiment was independently performed
in duplicate.
FIG. 4. Inhibition of ERK1/2 prolongs the half-life of PPAR
proteins in adipocytes. PPAR expression was measured in the pres-
ence of 5 M cycloheximide (CH) (A) or under steady-state conditions (B)
under control or IFN (100 units/ml)-treated conditions. Where indi-
cated, the 3T3-L1 adipocytes were pretreated for 45 min with the MEK
inhibitor (MEK I), U0126 (5 M). B, the cells were harvested after a 2-h
incubation in the presence or absence of IFN. One hundred micro-
grams of each extract was separated by SDS-PAGE, transferred to
nitrocellulose, and subjected to Western blot analysis. Samples were
processed, and results were visualized as described in the Fig. 1 legend.
The molecular mass of each protein is indicated to the left of the blots
in kilodaltons. This was a representative experiment independently
performed three times.
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in the absence or presence of LMB. Mdm2 has been character-
ized as an ubiquitin ligase (E3) that shuttles between the
nucleus and cytoplasm and is required for the degradation of
p53 (22). Although p53 expression is down-regulated during
differentiation of 3T3-L1 adipocytes, Mdm2 expression is main-
tained in fully differentiated 3T3-L1 adipocytes (45). Fig. 6B
demonstrates that Mdm2 accumulates in the nucleus in the
presence of LMB, indicating the effectiveness of LMB in these
experiments. These results demonstrate that CRM-1-depend-
ent nuclear export is not required for the degradation of PPAR
following IFN treatment and strongly suggests that PPAR is
degraded in the nucleus.
DISCUSSION
The novel observations in this study include the increased
ubiquitin conjugation of PPAR following IFN treatment, the
activation of PPAR transcriptional activity by IFN, evidence
that PPAR1 is substantially more labile than PPAR2, evi-
dence that serine phosphorylation of PPAR contributes to the
turnover of PPAR proteins in adipocytes, and evidence that
PPAR proteins are degraded by the nuclear ubiquitin-protea-
some system. These results and recent findings by Spiegelman
and co-workers (34) indicate that ubiquitin-proteasome-medi-
ated degradation of PPAR is an important contributor to the
cellular levels of PPAR proteins. Moreover, the cellular levels
of PPAR appear to be important because transgenic mice that
express half the normal amount of PPAR have been shown to
be more insulin sensitive (12).
In light of our current findings and the studies cited above
(13, 34, 39–41), we have formulated a model for the degrada-
tion of PPAR proteins in adipocytes. This model, illustrated in
Fig. 7, suggests that activation of PPAR by IFN, TZDs, or
endogenous ligands is followed by ubiquitin-proteasome-medi-
ated degradation. This model also suggests that serine phos-
phorylation contributes to PPAR degradation. The validity of
this model is addressed in the following paragraphs.
Our results demonstrate that both PPAR1 and PPAR2 are
targeted to proteasome under basal conditions and following
IFN treatment of adipocytes. We have also observed ubiquitin
conjugation of PPAR under basal conditions and demon-
strated a substantial increase in ubiquitin conjugation of
PPAR after IFN exposure. The increase in PPAR-ubiquitin
conjugates occurred within 15 min of IFN treatment and
precedes the decrease in PPAR observed in experiments
measuring PPAR degradation. Our results demonstrating
that proteasome inhibitors reduce the effect of IFN on PPAR
expression and the results demonstrating the appearance of
PPAR-polyubiquitin conjugates indicate that IFN treatment
in adipocytes results in the rapid degradation of PPAR via the
ubiquitin-proteasome pathway.
The rapid reduction in PPAR mRNA and protein levels
following IFN treatment (13) led us to predict that IFN
treatment would suppress PPAR activity in adipocytes. Sur-
prisingly, IFN treatment of 3T3-L1 adipocytes was associated
with the transcriptional activation of PPAR2. Although unex-
pected, this result is consistent with the idea that nuclear
hormone receptor turnover occurs concomitantly with tran-
scriptional activation of these transcription factors (24). Ligand-
FIG. 5. PPAR1 is more labile than PPAR2, and the higher
mobility form of PPAR1 decays after the lower mobility form.
A, whole cell extracts were prepared from fully differentiated 3T3-L1
adipocytes after incubation in the presence of 5 M cycloheximide for
the indicated time points. Incubations were carried out in the absence
(A) or presence (B) of IFN (100 units/ml). The lower panel (A) is an
enlargement of the indicated time points from the upper panel. One
hundred micrograms of each extract was separated by SDS-PAGE,
transferred to nitrocellulose, and subjected to Western blot analysis.
Samples were processed, and results were visualized as described in the
Fig. 1 legend. This was a representative experiment independently
performed three times.
FIG. 6. PPAR degradation in adipocytes does not depend on
nuclear export. A, fully differentiated 3T3-L1 adipocytes were incu-
bated in the presence of cycloheximide (5 M) and harvested at the
indicated time points. The adipocytes were treated with IFN alone or
in the presence of MG132 (20 M) or leptomycin B (10 nM) as indicated.
B, fully differentiated 3T3-L1 adipocytes were harvested after a 4-h
incubation in the presence of ethanol (LMB) or leptomycin B (LMB,
10 nM). Cytosolic and nuclear extracts were obtained as described under
“Experimental Procedures.” One hundred micrograms of each extract
were separated by SDS-PAGE, transferred to nitrocellulose, and sub-
jected to Western blot analysis. Samples were processed, and results
were visualized as described in the Fig. 1 legend. This was a represent-
ative experiment independently performed two times.
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dependent activation and subsequent degradation has been
demonstrated for several other nuclear hormone receptors (26–
30), and the paradigm of activation followed by ubiquitin-pro-
teasome-dependent degradation has been extended to proteins
such as protein kinase C (46). Although IFN has not been
shown to be a ligand for PPAR, the activation of PPAR is a
ligand-dependent process (47), and a recent study has demon-
strated that PPAR2 degradation is associated with the TZD-
induced activation of PPAR2 (34). Our data demonstrating
that IFN treatment results in both the activation of PPAR2
and the ubiquitin-proteasome-mediated degradation of PPAR
suggest that IFN-mediated signaling in adipocytes may be as-
sociated with the binding of an endogenous ligand and the acti-
vation and subsequent degradation of PPAR. Moreover, IFN-
induced PPAR2 transcriptional activation is enhanced in the
phosphorylation-deficient S112A mutant of PPAR2. This result
is consistent with previous findings showing that the mutation of
Ser112 to alanine in PPAR (Ser82 in PPAR1) is associated with
increased transcriptional activity (39, 40, 48).
The phosphorylation of PPAR by MAPKs has been de-
scribed in various studies (39–41, 48, 49). Although neither
IFN nor TZDs directly activate ERKs 1 and 2 in adipocytes,
we found that inhibition of these MAPKs resulted in an inhi-
bition of PPAR decay. Therefore, the mechanism(s) by which
MAPKs influence PPAR degradation is not clear. However,
phosphorylation plays an important role in targeting many
substrates for ubiquitination and can either inhibit or increase
the targeting of substrates to the ubiquitin-proteasome system
(22, 23). In our experiments, we observed that both PPAR1
and PPAR2 migrate as a doublet on gels that have been run
for 24–30 h (refer to Fig. 5). This doublet is easily distinguish-
able for PPAR1. We confirmed that the slower migrating form
corresponds to serine-phosphorylated PPAR1, and the faster
migrating form represents the unphosphorylated PPAR1 pro-
teins (data not shown), as has been previously described (34).
The results in Fig. 5 demonstrate that the faster migrating
form of PPAR1 disappears prior to the phosphorylated form of
the protein. The observed difference in the decay of these two
forms of PPAR1 suggest that phosphorylation of PPAR pro-
teins may serve as a ubiquitin-proteasome targeting signal in
which PPAR is converted to the phosphorylated form prior to
degradation by the ubiquitin-proteasome pathway. This hy-
pothesis is also consistent with the increased activation the
S112A mutant, and we predict that the ubiquitin-conjugating
machinery may not recognize the phosphorylation-deficient
PPAR as well as the wild-type protein. We hypothesize that
this may contribute to the increased activation observed with
the S112A mutant. This model is also supported by our data
demonstrating that inhibition of PPAR serine phosphoryla-
tion with the MEK inhibitor prolongs the half-life of PPAR
proteins. All of these results support the hypothesis that serine
phosphorylation of PPAR may influence its targeting to the
ubiquitin-proteasome system. However, recent work from the
Spiegelman laboratory (34) has shown that both the wild-type
and the S112A form of PPAR2 are degraded after ligand
activation, but they did not determine whether the half-lives of
these forms of the protein were different. Nonetheless, because
the phosphorylation-deficient mutant can be degraded, it
seems unlikely that serine phosphorylation is the only means
by which PPAR proteins are targeted to the ubiquitin-protea-
some system. Interestingly, the MAPK-regulated serine phos-
phorylation of the progesterone receptor has been shown act as
a targeting signal for the degradation of this protein (28, 50).
We also investigated the cellular location of the IFN-medi-
ated ubiquitin-proteasome-dependent degradation of PPAR.
PPAR proteins are predominantly localized in the nucleus,
and recent studies have demonstrated that the nuclear ubiq-
uitin-proteasome is active in the degradation of selected sub-
strates (42, 51, 52). Our results demonstrate that the IFN-
mediated degradation of PPAR does not require CRM1-
dependent nuclear export, indicating that IFN-induced
PPAR degradation likely occurs in the nucleus. In the absence
of serum deprivation, we observe active ERKs 1 and 2 in the
nucleus of 3T3-L1 adipocytes (data not shown) and hypothesize
that the presence of these kinases influences the nuclear decay
of PPAR proteins. Finally, the observation that PPAR1 is
substantially more labile than PPAR2 suggests that recogni-
tion of PPAR proteins by the ubiquitin-proteasome system in
adipocytes is influenced by the 30-amino acid N-terminal ex-
tension found in PPAR2. However, examination of the N-
terminal residues of both forms of PPAR reveals that neither
region contains the characteristic residues involved in the N-
end rule targeting to the ubiquitin-proteasome system (53).
Moreover, neither form contains a lysine residue necessary for
ubiquitin conjugation (22). However, this study does not ad-
dress the mechanisms underlying the differences in the half-
lives of PPAR1 and PPAR2.
Recent studies (12, 54) have shown that reduced PPAR
expression in mice (PPAR/) is associated with resistance to
weight gain along with protection from the insulin resistance
that typically accompanies weight gain. In addition, genetic
evidence indicates that decreased PPAR activity may protect
against insulin resistance in humans (55). Conversely, PPAR
is required for the formation of fat cells, and a lack of adipose
cells is associated with insulin resistance and hyperglycemia
(56). These studies suggest that a careful balance between
PPAR expression and activity levels must be maintained to
avoid development of diseases such as type II diabetes and
obesity. The current study, along with a previous study show-
ing that ligand activation of PPAR leads to ubiquitin-protea-
some-dependent degradation of PPAR (34), suggests that the
ubiquitin-proteasome pathway plays an important role in the
regulation of PPAR expression in adipocytes.
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